Health Policies

All Items

• Policy predictive model for better management of chronic obstructive pulmonary disease: economic-organisational implications in the Italian healthcare system

  Debora Antonini, Fausto De Michele, Claudio Micheletto, Dejan Radovanovic, Michele Basile, Eugenio Di Brino, Agostino Fortunato, Valentina Donati, Filippo Rumi

  223-230

  DOI: https://doi.org/10.33393/grhta.2024.3114

• Survival, treatment duration and costs of patients with prostate cancer treated with triptorelin in Italy: a study of administrative databases

  Orazio Caffo, Gaetano Facchini, Luca Degli Esposti, Valentina Acciai, Giorgio Mauri, Paola Mazzanti, Giuseppe Fornarini

  207-213

  DOI: https://doi.org/10.33393/grhta.2024.3055

• Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network

  Daniela Segala, Marco Barbieri, Mariachiara Di Nuzzo, Melissa Benazzi, Aurora Bonazza, Letizia Romanini, Brunella Quarta, Kristian Scolz, Anna Marra, Diana Campioni, Rosario Cultrera

  5-12

  DOI: https://doi.org/10.33393/grhta.2024.3094

• Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview

  Rosario Cultrera

  1-4

  DOI: https://doi.org/10.33393/grhta.2024.3108

• Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel

  Claudio Jommi, Francesca Patarnello, Cosetta Bianchi, Giuliano Buzzetti

  169-174

  DOI: https://doi.org/10.33393/grhta.2024.3107

• Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases

  Cristian Lolli, Antonio Verde, Luca Degli Esposti, Valentina Acciai, Alessia Brigido, Emanuela Proietti, Sarah Scagliarini

  154-160

  DOI: https://doi.org/10.33393/grhta.2024.2892

• Exploring the administrative burden faced by hematologists: a comprehensive study in Italy

  Davide Petruzzelli, Marco Vignetti, Stefania Trasarti, Paolo Sportoletti, Silvia Della Torre, Roberto Cairoli, Francesca Pia Chiara Leone, Giuseppe Pompilio, Marco Gullì, Eva Brown Hajdukova, Davide Integlia

  161-168

  DOI: https://doi.org/10.33393/grhta.2024.3042

• Early access programs for medicines: a reform proposal for the Italian National Health Service

  Patrizia Popoli, Giovanni Giuliani, Arturo Cavaliere, Claudio Jommi

  148-153

  DOI: https://doi.org/10.33393/grhta.2024.3098

• How effective are prescriptive governance tools? Results from the application of AIFA notes

  Giaele Moretti, Benedetta Dal Canto, Francesco Attanasio, Alma Martelli, Francesca Ferrè

  131-137

  DOI: https://doi.org/10.33393/grhta.2024.3027

• The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health Service

  Claudio Jommi, Federico Pantellini, Giovanni Giuliani, Marianna Cavazza

  115-123

  DOI: https://doi.org/10.33393/grhta.2024.2735

• Regional administrative data and their role in planning, programming and controlling at regional level

  Irene Marzona, Paolo Stella, Gianluca Trifirò, Giovanni Corrao

  101-104

  DOI: https://doi.org/10.33393/grhta.2024.3024

• Regional Formularies in Italy: current state and future perspectives

  Alberto Bortolami, Claudio Jommi, Filippo Bresciani, Luca Piccoli, Elisa Sangiorgi, Giovanna Scroccaro

  68-74

  DOI: https://doi.org/10.33393/grhta.2024.2677

• HTA regulation: how is Italy moving?

  Francesca Patarnello

  51-54

  DOI: https://doi.org/10.33393/grhta.2024.3025

• Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)

  Silvia Calabria, Manenti Lucio, Giulia Ronconi, Carlo Piccinni, Leonardo Dondi, Letizia Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, Nello Martini

  22-30

  DOI: https://doi.org/10.33393/grhta.2024.2696

• The future of drugs distribution in the National Health System

  Massimo Medaglia, Giuliano Buzzetti, Marco Cossolo, Paola Deambrosis, Giovanna Scroccaro

  17-21

  DOI: https://doi.org/10.33393/grhta.2024.2619

• A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

  Michele Basile, Ilaria Valentini, Roberto Attanasio, Renato Cozzi, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Renata Simona Auriemma, Ernesto De Menis, Felice Esposito, Emanuele Ferrante, Giuseppe Iatì, Diego Mazzatenta, Maurizio Poggi, Roberta Rudà, Fabio Tortora, Fabio Cruciani, Zuzana Mitrova, Rosella Saulle, Simona Vecchi, Paolo Cappabianca, Agostino Paoletta, Alessandro Bozzao, Marco Caputo, Francesco Doglietto, Francesco Ferraù, Andrea Gerardo Lania, Stefano Laureti, Stefano Lello, Davide Locatelli, Pietro Maffei, Giuseppe Minniti, Alessandro Peri, Chiara Ruini, Fabio Settanni, Antonio Silvani, Nadia Veronese, Franco Grimaldi, Enrico Papini, Americo Cicchetti

  1-16

  DOI: https://doi.org/10.33393/grhta.2024.2601

• Orphan drugs in Italy: availability and time-to-access at regional level

  Maria Lucia Marino, Eva Alessi, Aurora Di Filippo, Barbara Polistena, Francesco Macchia, Federico Spandonaro, Francesco Trotta

  89-97

  DOI: https://doi.org/10.33393/grhta.2023.2641

• Time to market access in Italy: duration of the P&R process for rare disease drugs

  Andrea Marcellusi, Paola Raimondo, Carlotta Galeone, Pier Luigi Canonico

  79-88

  DOI: https://doi.org/10.33393/grhta.2023.2610

• Unmet need: definitions, literature evidence and implications for HTA

  Claudio Jommi, Michela Meregaglia, Carmine Pinto

  70-78

  DOI: https://doi.org/10.33393/grhta.2023.2624

• Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members

  Eugenio Di Brino, Claudio Jommi

  40-45

  DOI: https://doi.org/10.33393/grhta.2023.2562

• The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy

  Francesco Malandrini, Cesare Borroni, Michela Meregaglia, Massimiliano Sarra, Oriana Ciani

  12-17

  DOI: https://doi.org/10.33393/grhta.2023.2514

• Drugs territorialization in the era of PNRR: perspectives, opportunities and considerations from a panel of experts

  Anna Maria Marata, Walter Marrocco, Emanuela Arcangeli, Mattia Battistini, Giuliano Buzzetti, Riccardo Candido, Gianluigi Casadei, Francesco Cattel, Arturo Cavaliere, Agostino Consoli, Giovanni Corrao, Guido Didoni, Mauro Di Gesù, Alberto Giovanzana, Matteo Lenzi, Massimo Medaglia, Marta Meloncelli, Stefano Palcic, Marcello Pani, Francesca Patarnello, Emanuele Pria, Dario Scaduto, Valeria Tozzi, Marco Zibellini, Elisa Crovato

  155-158

  DOI: https://doi.org/10.33393/grhta.2022.2495

• Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness

  Francesca Patarnello, Emiliano Briante, Federico Villa

  117-122

  DOI: https://doi.org/10.33393/grhta.2022.2440

• Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness

  Claudio Jommi, Giovanni Apolone, Giovanna Scroccaro, Valentina Acciai, Antonio Addis, Andrea Ardizzoni, Renato Bernardini, Alberto Bortolami, Alessia Brigido, Giuliano Buzzetti, Pier Luigi Canonico, Francesca Caprari, Stefano Centanni, Chiara Cernetti, Americo Cicchetti, Giorgio Corsico, Francesco Damele, Filippo De Braud, Sara Manurita, Francesco Saverio Mennini, Irene Olivi, Federica Parretta, Lara Pippo, Stefania Pulimeno, Massimo Riccaboni, Giuseppe Rossi, Cecilia Saleri, Alessandra Sinibaldi, Federico Spandonaro, Cristian Stefenoni, Elena Visentin, Pierluigi Viale, Giuseppina Zapparelli, Patrizia Popoli

  99-104

  DOI: https://doi.org/10.33393/grhta.2022.2475

• The potential impact of PNNR on the management of patients with epilepsy

  Francesco Saverio Mennini

  1-3

  DOI: https://doi.org/10.33393/grhta.2022.2445